Method and kit for evaluating onset risk of type b liver cancer on chronic hepatitis b patient
The method and kit for detecting HBx antigen protein and HLA-DPB1 gene mutations in chronic hepatitis B patients provide a more accurate assessment of hepatic cancer risk, facilitating targeted testing and early detection.
Patent Information
- Application Number
- JP2023079021
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-22
AI Technical Summary
Current methods are inadequate for accurately assessing the risk of chronic hepatitis B patients developing hepatic cancer, as some patients with susceptible or resistant HLA-DPB1 alleles still develop or do not develop the disease, limiting practical evaluation of risk.
A method and kit for evaluating the risk of chronic hepatitis B patients developing hepatic cancer by detecting specific amino acid mutations in the HBx antigen protein and HLA-DPB1 gene, specifically K130M and H94Y mutations, using genetic and protein-level analysis.
Enables more precise evaluation of the risk of hepatic cancer in chronic hepatitis B patients, allowing for targeted testing frequency and early detection, reducing medical burden and anxiety for low-risk patients and enabling less invasive treatments.
Smart Images

Figure 2024163432000001 
Figure 2024163432000002 
Figure 2024163432000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a method and a kit for evaluating the risk of developing type B hepatocellular carcinoma in a patient with chronic hepatitis B. [Background technology]
[0002] It is said that one-third of the world's population is infected with the hepatitis B virus (HBV). Hepatitis B is broadly divided into transient infections that subside after a short time and chronic hepatitis. Symptoms of acute hepatitis appear after an incubation period of one to six months after infection, and the patient begins to recover within a few weeks. However, 1-2% of patients who develop acute hepatitis are at risk of developing fulminant hepatitis, and 70-80% of those who develop fulminant hepatitis will die.
[0003] On the other hand, if the infected HBV is not eliminated from the body and resides in the liver for more than six months, the individual becomes a carrier. In cases of mother-to-child infection or childhood infection, the majority of cases develop chronic hepatitis, and approximately 0.3% develop cirrhosis or liver cancer annually. In cases of adults being infected, approximately 90% of carriers go through an asymptomatic stage, a transient hepatitis stage, and a hepatitis remission stage, and then remain asymptomatic carriers. However, approximately 10% of adult infected individuals progress to chronic hepatitis, and of these, approximately 1% progress to cirrhosis or liver cancer. Chronic hepatitis B virus patients are widely distributed in Southeast Asia and the East Pacific region, and it is said that there are approximately 1.5 million people infected with hepatitis B in Japan.
[0004] As described above, the course of HBV infection varies widely. In recent years, the search for host-side genetic factors has progressed, and genome-wide association studies (GWAS) using Asian samples, including Japanese, have reported new genetic factors associated with chronic hepatitis B (CHB).
[0005] For example, Patent Document 1 describes that alleles susceptible to chronic hepatitis B are HLA-DPB1*05:01 and HLA-DPB1*09:01, alleles resistant to chronic hepatitis B are HLA-DPB1*04:02, HLA-DPB1*04:01 and HLA-DPB1*02:01, and alleles resistant to the progression of the pathology of hepatitis B are HLA-DPB1*02:01. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2015 / 030142 Summary of the Invention [Problem to be solved by the invention]
[0007] However, even among chronic hepatitis B patients with HLA-DPB1*05:01, which is considered to be an allele that is susceptible to the progression of hepatitis B disease, there are patients who develop hepatocellular carcinoma (HCC) and those who do not. The odds ratio in the 95% confidence interval between the hepatocellular carcinoma B-developing group and the healthy control group is about 1.5, so it cannot be said that the risk of developing hepatocellular carcinoma B in chronic hepatitis B patients can be evaluated with practical accuracy.
[0008] Furthermore, even among chronic hepatitis B patients with HLA-DPB1*02:01, an allele that is considered resistant to the progression of hepatitis B disease, there are patients who develop hepatocellular carcinoma (HCB) and those who do not. The odds ratio in the 95% confidence interval between the HCC B group and the healthy control group is about 0.5, so it cannot be said that the risk of developing hepatocellular carcinoma (HCB) in chronic hepatitis B patients can be evaluated with practical accuracy.
[0009] Therefore, there is a need for a more practical method for evaluating the risk of developing hepatocellular carcinoma (HC) in patients with chronic hepatitis B. Therefore, an object of the present invention is to provide a technique for evaluating the risk of developing hepatocellular carcinoma (HC) in patients with chronic hepatitis B. [Means for solving the problem]
[0010] The present invention includes the following aspects. [1] A method for evaluating the risk of a patient with chronic hepatitis B developing type B hepatocellular carcinoma, wherein either (i) or (ii) below indicates that the patient with chronic hepatitis B has a high risk of developing type B hepatocellular carcinoma: (i) the patient with chronic hepatitis B has a homozygous HLA-DPB1*05:01 gene, and the HBx antigen protein of the hepatitis B virus infecting the patient with chronic hepatitis B has an amino acid mutation of K130M; (ii) the patient with chronic hepatitis B has a heterozygous HLA-DPB1*05:01 gene, and the HBx antigen protein of the hepatitis B virus infecting the patient with chronic hepatitis B has an amino acid mutation of H94Y; [2] A kit for assessing the risk of developing hepatocellular carcinoma (HBC) in patients with chronic hepatitis B, comprising a reagent for detecting the HLA-DPB1*05:01 gene and a reagent for detecting the K130M or H94Y amino acid mutation in the HBx antigen protein of the hepatitis B virus. Effect of the Invention
[0011] According to the present invention, a technique for evaluating the risk of developing type B hepatocellular carcinoma in patients with chronic hepatitis B can be provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] [Methods for assessing the risk of developing hepatocellular carcinoma in patients with chronic hepatitis B] In one embodiment, the present invention provides a method for evaluating a risk of a chronic hepatitis B patient developing type B hepatocellular carcinoma, wherein either (i) or (ii) below indicates that the chronic hepatitis B patient has a high risk of developing type B hepatocellular carcinoma: (i) The patient with chronic hepatitis B has the HLA-DPB1*05:01 gene in homozygous form, and the HBx antigen protein of the hepatitis B virus infecting the patient with chronic hepatitis B has the amino acid mutation K130M. (ii) The patient with chronic hepatitis B has a heterozygous HLA-DPB1*05:01 gene, and the HBx antigen protein of the hepatitis B virus infecting the patient with chronic hepatitis B has an amino acid mutation of H94Y.
[0013] Chronic hepatitis B refers to a state of persistent infection with HBV. Causes of onset include mother-to-child transmission (vertical infection) from a patient with persistent HBV infection, when the blood or bodily fluids of a patient with persistent HBV infection enter the body due to medical procedures during infancy, when a patient becomes infected with HBV while taking immunosuppressants or anticancer drugs that weaken the body's immune system and is unable to eliminate HBV from the body, and when a healthy person becomes infected with an exotic species of HBV such as the Western type known as genotype A or the Asian / African type.
[0014] When infected in adulthood, about 90% of HBV-infected people become asymptomatic carriers, but about 10% progress to chronic hepatitis B. Furthermore, some of these progress to cirrhosis or liver cancer. "Cirrhosis" refers to a condition in which fibers formed when the liver damaged by HBV infection is repaired spread to the liver, causing ascites and esophageal varices due to liver hardening, and hepatic encephalopathy and jaundice due to decreased liver function. Hepatocellular carcinoma (HCC) is hepatocellular carcinoma caused by HBV infection.
[0015] In the method of this embodiment, the risk of a chronic hepatitis B patient developing type B hepatocellular carcinoma is evaluated based on the genotype of the HLA-DPB1 allele of the chronic hepatitis B patient and the mutation of HBV that infects the chronic hepatitis B patient.
[0016] HLA is a human major histocompatibility complex (MHC), a membrane protein that binds to foreign antigen peptides from grafts, bacteria, viruses, etc., and presents them to T cells. Many alleles are known to exist in HLA, and information on these is described in the HLA nomenclature (http: / / hla.alleles.org / nomenclature / naming.html) and the like. The notation of alleles in this specification is based on the notation method of the HLA nomenclature.
[0017] The European Molecular Biology Laboratory database (EMBL-EBI) accession numbers for the nucleotide sequence of the cDNA of HLA-DPB1*05:01 are AY656679, etc., and the EMBL-EBI accession numbers for the amino acid sequence of HLA-DPB1*05:01 are AAV71026, etc.
[0018] The method for determining the genotype of the HLA-DPB1 allele is not particularly limited, and can be appropriately selected from methods known to those skilled in the art. For example, the polymerase chain reaction-sequence specific oligonucleotide probe method (PCR-SSOP method), allele-specific oligonucleotide (ASO) method, TaqMan (registered trademark) PCR method, MALDI-TOF / MS method, direct sequencing method, RFLP method, Invader method, TGGE method, DGGE method, MutY enzyme method, microarray, protein truncation test (PTT) method, Snipper method, Luminex method, HLA Imputation method, micro SSP method, etc. are mentioned. Among them, the PCR-SSOP method, direct sequencing method, Luminex method, HLA Imputation method, and micro SSP method are preferable.
[0019] The direct sequencing method may be a conventional direct sequencing method or a direct sequencing method using a next-generation sequencer. The HLA imputation method is a genetic statistical analysis method that uses a computer to estimate an individual's HLA genotype with high accuracy. The micro-SSP method is a method in which PCR amplification is performed using multiple primers, and whether or not a characteristic polymorphic portion has been amplified is confirmed by gel electrophoresis, and the allele is determined based on the amplification pattern.
[0020] The determination of the genotype of the allele (typing) can be performed at the gene level or protein level. The genotype of the HLA-DPB1 allele can be determined by preparing genomic DNA or mRNA by a general method from a biological sample collected from a chronic hepatitis B patient who is to be evaluated for the risk of developing hepatocellular carcinoma of type B, and analyzing the base sequence of the HLA-DPB1 allele.
[0021] The patient with chronic hepatitis B targeted by the method of this embodiment may be Japanese. In addition, examples of biological samples that can be used include, but are not limited to, peripheral blood mononuclear cells, tissues, hair, stool, urine, saliva, cells, cells scraped from the nasal mucosa, and cells scraped from the oral mucosa.
[0022] The mutation of HBV infecting a patient with chronic hepatitis B can be detected by analyzing the base sequence of HBV derived from the patient or an amino acid sequence based thereon and comparing it with a reference sequence. The mutation of HBV may be detected at the DNA level or the amino acid sequence level. The HBV derived from a patient can be collected, for example, from a blood sample derived from the patient. The genotype of HBV targeted by the method of this embodiment may be HBV / C.
[0023] In this embodiment, the base sequence of the HBx gene of HBV may be sequenced to detect the amino acid mutations K130M and H94Y in the HBx antigen protein. Alternatively, each mutation may be detected by PCR, the Invader method, or the like, using primers or probes capable of detecting gene mutations corresponding to these amino acid mutations. Alternatively, each amino acid mutation may be detected at the protein level using monoclonal antibodies capable of detecting each amino acid mutation.
[0024] The NCBI accession number of the cDNA of the HBx gene is LC535924 (gene=”X”), etc., and the NCBI accession number of the amino acid sequence of the HBx antigen protein is BCD41111, etc.
[0025] As described later in the Examples, the inventors have revealed that patients with chronic hepatitis B are at high risk of developing hepatocellular carcinoma (HBC) if either (i) or (ii) below is met. (i) A patient with chronic hepatitis B has the homozygous HLA-DPB1*05:01 gene, and the HBx antigen protein of the HBV infecting the patient with chronic hepatitis B has the amino acid mutation K130M. (ii) The chronic hepatitis B patient has a heterozygous HLA-DPB1*05:01 gene, and the HBx antigen protein of the HBV infecting the chronic hepatitis B patient has the amino acid mutation H94Y.
[0026] As used herein, a high risk of developing type B hepatocellular carcinoma means that the odds ratio in the 95% confidence interval between the type B hepatocellular carcinoma patient group and the chronic hepatitis B patient group is 2 or more, preferably 3 or more, and more preferably 4 or more.
[0027] Here, the odds ratio, in the case of (i) above, is the ratio of the odds of developing type B hepatocellular carcinoma (type B hepatocellular carcinoma patients) to the odds of not developing type B hepatocellular carcinoma (type B chronic hepatitis patients) for patients who have the homozygous HLA-DPB1*05:01 gene and whose HBx antigen protein of the infecting HBV has the amino acid mutation K130M.
[0028] In the case of (ii) above, the odds are the ratio of the odds of developing type B hepatocellular carcinoma to the odds of not developing type B hepatocellular carcinoma for patients who have the heterozygous HLA-DPB1*05:01 gene and whose HBV HBx antigen protein has the H94Y amino acid mutation.
[0029] According to the method of this embodiment, the risk of chronic hepatitis B patients developing hepatocellular carcinoma (HBC) can be evaluated with a more practical accuracy than conventional methods.
[0030] [A kit for assessing the risk of developing hepatocellular carcinoma in patients with chronic hepatitis B] In one embodiment, the present invention provides a kit for assessing the risk of a patient with chronic hepatitis B developing type B hepatocellular carcinoma, comprising a reagent for detecting the HLA-DPB1*05:01 gene and a reagent for detecting the K130M or H94Y amino acid mutation in the HBx antigen protein of hepatitis B virus.
[0031] The kit of this embodiment can suitably carry out the above-mentioned method for evaluating the risk of developing type B hepatocellular carcinoma in a patient with chronic hepatitis B.
[0032] The reagent for detecting the HLA-DPB1*05:01 gene is not particularly limited as long as it can detect this allele, and examples thereof include a primer set specific to this allele, a probe, deoxynucleotide triphosphates (dNTPs), DNA polymerase, a buffer solution, etc. Furthermore, the primer or probe may be labeled with a fluorescent substance, biotin, digoxigenin, etc.
[0033] In addition, from the viewpoint of determining whether the HLA-DPB1 allele is homozygous or heterozygous, the kit of this embodiment may further include a primer set or probe for determining an HLA-DPB1 allele of a genotype other than the HLA-DPB1*05:01 allele.
[0034] A reagent for detecting the K130M or H94Y amino acid mutation in the HBx antigen protein of Hepatitis B virus may be a reagent for determining the base sequence of a region of the HBx gene that includes at least the gene region encoding the above-mentioned mutated portion.
[0035] For example, there may be mentioned a primer set for amplifying the gene region encoding the 130th or 94th amino acid of the HBx antigen protein, a reagent for determining the base sequence, and the like.
[0036] Alternatively, it may be a primer set or probe capable of detecting a mutation in the HBx gene corresponding to the amino acid mutation K130M or H94Y in the HBx antigen protein.
[0037] Alternatively, it may be a monoclonal antibody capable of detecting each amino acid mutation on the HBx antigen protein at the protein level.
[0038] [Other embodiments] In one embodiment, the present invention provides a method for treating hepatitis B, comprising: (i) a patient with chronic hepatitis B having HLA-DPB1*05:01 gene in homozygous form and an HBx antigen protein of the hepatitis B virus infecting the patient with chronic hepatitis B having an amino acid mutation of K130M; or (ii) a patient with chronic hepatitis B having HLA-DPB1*05:01 gene in heterozygous form and an HBx antigen protein of the hepatitis B virus infecting the patient with chronic hepatitis B having an amino acid mutation of H94Y, indicating that the patient with chronic hepatitis B has a high risk of developing hepatitis B; and when the patient with chronic hepatitis B has a high risk of developing hepatitis B, increasing the frequency of testing for hepatitis B cancer in the patient with chronic hepatitis B to detect the onset of hepatitis B cancer at an early stage; and treating the detected early stage hepatitis B cancer by medical treatment, surgical treatment, or anticancer drug treatment. In addition, when the risk is low, reducing the frequency of testing not only has medical economic benefits, but also reduces the burden on patients associated with visiting medical clinics.
[0039] In this embodiment, the HLA-DPB1*05:01 gene, the Hepatitis B virus mutation, and the like are the same as those described above.
[0040] At present, it is not possible to predict who is at high risk of liver cancer. It is said that in cases where the infection pattern is childhood, approximately 0.3% of chronic hepatitis patients will develop liver cancer annually, and in cases where the infection occurs in adulthood, approximately 1% of chronic hepatitis patients will develop liver cancer. Although the number of patients who develop liver cancer is small compared to the total number of infected people, at present it is not possible to predict who is at high risk of liver cancer, so all patients are observed at regular intervals in the outpatient clinic and undergo regular non-invasive tests (imaging tests such as ultrasound and MRI) to check the condition of their livers.
[0041] In the method of the present embodiment, increasing the frequency of testing may mean, for example, testing for the development of hepatocellular carcinoma type B, which is usually performed about once every 2 to 3 years, or more frequently, while decreasing the frequency of testing may mean reducing the frequency to about once every 5 years, etc.
[0042] It is preferable from the viewpoint of medical economy to limit the subjects for whom increased testing frequency should be provided to those at high risk of developing type B hepatocellular carcinoma. In addition, for patients with chronic hepatitis B who have been shown to have a low risk of developing type B hepatocellular carcinoma, this can alleviate the mental anxiety and stress associated with the development of type B hepatocellular carcinoma.
[0043] The method of the present embodiment makes it possible to detect the onset of hepatocellular carcinoma type B early, and to select a less invasive treatment method for hepatocellular carcinoma type B. The medical treatment includes, for example, a relatively less invasive treatment such as radiofrequency ablation therapy. EXAMPLES
[0044] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.
[0045] [Experimental Example 1] (HLA allele detection) Genomic DNA was prepared from peripheral blood mononuclear cells derived from Japanese patients with hepatocellular carcinoma type B and healthy subjects (without hepatitis B infection), and the genotypes of HLA-DPB1 alleles were determined.
[0046] A QIAamp® DNA Mini kit (Qiagen) was used to prepare genomic DNA. First, 20 μL of QIAGEN Protease and 200 μL of each sample were added to a microtube. Buffer AL was then added and mixed for 15 seconds, and the sample was then incubated at 56° C. for 10 minutes to dissolve the sample. The microtube was then spun down for a few seconds to collect the solution on the inside of the lid. Next, 200 μL of ethanol (100%) was added to the sample, and the sample was vortexed for 15 seconds, after which the 1.5 mL microtube was spun down for a few seconds to collect the solution on the inside of the lid. The solution was applied to a QIAamp® Mini Spin Column and centrifuged at 6,000×g for 1 minute. Next, the QIAamp® Mini Spin Column was opened, 500 μL of Buffer AW1 was added, and the sample was centrifuged at 6,000×g for 1 minute. Next, the QIAamp Mini Spin Column was opened, 500 μL of Buffer AW2 was added, and centrifuged at 20,000×g for 3 minutes. Next, the QIAamp Mini Spin Column was opened, and 200 μL of Buffer AE or purified water was added. After incubation at room temperature for 1 minute, genomic DNA from each sample was recovered by centrifugation at 6,000×g for 1 minute.
[0047] Using the prepared genomic DNA sample, 4-digit HLA typing was performed using the LABType SSO DPA1 / DPB1 kit (One Lambda) using the PCR-SSOP method, or the WAKFlow (registered trademark) HLA-DPB1 typing kit (Wakunaga Pharmaceutical). The experiment was performed according to the instructions, and measurements were performed using a multiplex measurement system (Luminex) using xMAP (registered trademark) technology. Specifically, 24.5 μL of amplification reagent and 0.5 μL of DNA polymerase solution were added to 2 μL of the above genomic DNA sample, and a PCR reaction was performed under the following conditions. Denaturation temperature: 93℃ (30 seconds) Annealing temperature: 60℃ (30 seconds) Extension temperature: 72℃ (30 seconds) Number of cycles: 40 The reaction was carried out at 93°C (3 minutes) before the above cycle and at 72°C (5 minutes) after the above cycle, and then stored at 4°C.
[0048] After PCR, 5 μL of amplified DNA was added to each well of a 96-well PCR plate containing 5 μL of denaturing solution, vortexed, and left at room temperature for 5 minutes. The above denatured amplified DNA was added to 25 μL of hybridization reagent, which was a mixture of 20 μL of hybridization solution, 3 μL of bead mix, and 2 μL of SAPE, to prepare a hybridization solution, which was then vortexed. The above hybridization solution was set in a thermal cycler set at 55°C, and hybridization was performed for 30 minutes. 75 μL of washing solution was added to each well, and the mixture was centrifuged at 1,000 × g for 1 minute. The supernatant was then removed, and 75 μL of washing solution was added to each well. The block temperature of the Luminex XYP was set to 37°C, and measurements were performed using a template file corresponding to the lot number of the bead mix. The CSV file of the measurement results was opened with WAKFlow (registered trademark) Typing Software, and the positive and negative results of each fluorescent bead were automatically determined based on the cutoff values listed in the judgment table. In the automatic judgment, beads showing a fluorescence intensity above the cutoff value were judged as positive, and beads showing a fluorescence intensity below the cutoff value were judged as negative, and the HLA genotype was determined from the positive / negative pattern of each bead. The results are shown in Table 1.
[0049] [Table 1]
[0050] As a result, it was shown that the HLA-DPB1*05:01 and HLA-DPB1*09:01 alleles are susceptible to the development of type B hepatocellular carcinoma. In addition, it was shown that the HLA-DPB1*02:01, HLA-DPB1*04:01, and HLA-DPB1*04:02 alleles are resistant to the development of type B hepatocellular carcinoma.
[0051] However, among patients who have an allele that is susceptible to the development of hepatocellular carcinoma type B, there are patients who develop hepatocellular carcinoma type B and patients who do not, making this method impractical for evaluating the risk of developing hepatocellular carcinoma type B. Also, among patients who have an allele that is resistant to the development of hepatocellular carcinoma type B, there are patients who develop hepatocellular carcinoma type B and patients who do not, making this method impractical for evaluating the risk of developing hepatocellular carcinoma type B.
[0052] [Experimental Example 2] (Detection of Hepatitis B Virus Population Mutation Frequencies 1) We analyzed and compared the gene sequences of hepatitis B virus (HBV) contained in blood samples from patients with hepatocellular carcinoma type B and chronic hepatitis type B who were homozygous for the HLA-DPB1*05:01 allele.
[0053] Patients with matching age and HBV genotype were analyzed. HBV / C is a type of hepatitis B virus that commonly infects Japanese and other Asians. In this case, age, sex, and HBV genotype, which are known to be related to the development of liver cancer, were adjusted so that there were no differences between cases (with liver cancer) and controls (without liver cancer). Specifically, the average age of the hepatitis B patients was 63 years old (99 cases), and the average age of the chronic hepatitis B patients was 61 years old (101 cases), and all were male. Furthermore, the genotype of the infected HBV in all cases was HBV / C.
[0054] The HBs gene region encoding the highly antigenic HBs antigen and the HBx gene region encoding the HBx antigen were amplified by PCR. The amplified PCR products were then subjected to deep sequencing analysis using a high-speed sequencer. The high-speed sequencers used were GS Junior (Roche) or Miseq (Illumina).
[0055] Based on the obtained base sequence, HBV mutation variations were listed and the amino acid mutation patterns were obtained. The general amino acid sequence of HBV / C was used as the standard. As a result, it was revealed that the amino acid mutation K130M at the 130th amino acid sequence of HBx antigen is highly associated with the development of type B hepatocellular carcinoma.
[0056] Table 2 below shows the amino acid sequence of the 130th amino acid of the HBx antigen of HBV that infected type B hepatocellular carcinoma patients and chronic hepatitis B patients, and the proportion of the amino acid sequence present.
[0057] [Table 2]
[0058] Table 3 below shows the results of calculating statistical indicators of the likelihood of a patient who is homozygous for the HLA-DPB1*05:01 allele to develop type B hepatocellular carcinoma when the HBV that infected the patient has the K130M amino acid mutation in HBx antigen.
[0059] [Table 3]
[0060] As a result, a high odds ratio was shown, demonstrating that this is a practical indicator for assessing the risk of developing hepatocellular carcinoma in patients with chronic hepatitis B.
[0061] [Experimental Example 3] (Detection of mutation frequency in Hepatitis B virus populations 2) We analyzed and compared the gene sequences of hepatitis B virus (HBV) contained in blood samples from patients with type B hepatocellular carcinoma and patients with chronic hepatitis B who were heterozygous for the HLA-DPB1*05:01 allele.
[0062] Patients with matching age and HBV genotype were analyzed. Age, sex, and HBV genotype, which are considered to be related to the development of liver cancer, were adjusted so that there were no differences between cases (with liver cancer) and controls (without liver cancer). Specifically, the average age of the type B liver cancer patients was 62 years old (26 cases), and the average age of the type B chronic hepatitis patients was 63 years old (52 cases), and all were male. The genotype of the infected HBV in all cases was HBV / C.
[0063] The HBs gene region encoding the highly antigenic HBs antigen and the HBx gene region encoding the HBx antigen were amplified by PCR. The amplified PCR products were then subjected to deep sequencing analysis using a high-speed sequencer. The high-speed sequencers used were GS Junior (Roche) or Miseq (Illumina).
[0064] Based on the obtained base sequence, HBV mutation variations were listed and the amino acid mutation patterns were obtained. The general amino acid sequence of HBV / C was used as the standard. As a result, it was revealed that the amino acid mutation H94Y at the 94th amino acid sequence of HBx antigen is highly associated with the development of type B hepatocellular carcinoma.
[0065] Table 4 below shows the 94th amino acid sequence of HBx antigen of HBV that infected type B hepatocellular carcinoma patients and chronic hepatitis B patients, and the proportion of the same present.
[0066] [Table 4]
[0067] Table 5 below shows the results of calculating statistical indicators of the likelihood of a patient who has the HLA-DPB1*05:01 allele in a heterozygous form to develop type B hepatocellular carcinoma when the HBV that has infected the patient has the H94Y amino acid mutation in HBx antigen.
[0068] [Table 5]
[0069] As a result, a high odds ratio was shown, demonstrating that this is a practical indicator for assessing the risk of developing hepatocellular carcinoma in patients with chronic hepatitis B. [Industrial Applicability]
[0070] According to the present invention, a technique for evaluating the risk of developing type B hepatocellular carcinoma in patients with chronic hepatitis B can be provided.
Claims
1. A method for assessing a risk of developing hepatocellular carcinoma (HBC) in a patient with chronic hepatitis B, comprising: The method according to claim 1, wherein either (i) or (ii) below indicates that the patient with chronic hepatitis B is at high risk of developing hepatocellular carcinoma (HBC): (i) the patient with chronic hepatitis B has a homozygous HLA-DPB1*05:01 gene, and the HBx antigen protein of the hepatitis B virus infecting the patient with chronic hepatitis B has an amino acid mutation of K130M; (ii) the patient with chronic hepatitis B has a heterozygous HLA-DPB1*05:01 gene, and the HBx antigen protein of the hepatitis B virus infecting the patient with chronic hepatitis B has an amino acid mutation of H94Y;
2. A kit for assessing the risk of developing hepatocellular carcinoma (HBC) in a patient with chronic hepatitis B, comprising a reagent for detecting the HLA-DPB1*05:01 gene and a reagent for detecting the amino acid mutations K130M or H94Y in the HBx antigen protein of the hepatitis B virus.
Citation Information
Patent Citations
Method for detecting predisposition for hepatitis b to become chronic
WO2015030142A1
